Acute Coronary Syndrome - Pipeline Insight, 2025: Targeted Therapies and Cardioprotective Innovations Reshape Post-Event Care | DelveInsight

Acute Coronary Syndrome (ACS), a life-threatening manifestation of coronary artery disease encompassing unstable angina, NSTEMI, and STEMI, continues to be a major global health burden. Despite advancements in percutaneous coronary interventions and dual antiplatelet therapy, patients with ACS remain at elevated risk for recurrent events, heart failure, and long-term mortality. This persistent unmet need is fueling innovation in the ACS treatment pipeline, with a focus on cardioprotective agents, anti-inflammatory modulators, lipid-lowering therapies, and antithrombotic drugs with improved safety profiles.

DelveInsight's "Acute Coronary Syndrome - Pipeline Insight, 2025" tracks over 5+ active clinical assets targeting various pathophysiological pathways involved in ACS. Key areas of innovation include PCSK9 inhibitors, Factor XIa inhibitors, colchicine-based anti-inflammatories, and novel agents aimed at ischemia-reperfusion injury. Prominent players such as Janssen Research & Development, DalCor Pharmaceuticals, and Hyloris Pharmaceuticals are advancing differentiated assets for both acute and post-ACS settings.

The report provides comprehensive insights into trial designs, biomarker-driven strategies, and evolving endpoints that emphasize long-term cardiovascular outcomes. As regulatory bodies prioritize high-risk cardiovascular populations, a surge in development collaborations and precision medicine approaches is redefining ACS management.

With the growing recognition of inflammation, residual lipid risk, and platelet biology in post-ACS care, the pipeline is shifting from acute stabilization to long-term cardioprotection. This evolution marks a new chapter in ACS treatment, to reduce recurrence and improve quality of life in high-risk cardiovascular patients.

Interested in learning more about the current treatment landscape and the key drivers shaping the Acute Coronary Syndrome pipeline? Click here: https://www.delveinsight.com/report-store/acute-coronary-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Acute Coronary Syndrome Pipeline Report
• DelveInsight's Acute Coronary Syndrome pipeline analysis depicts a strong space with 5+ active players working to develop 5+ pipeline drugs for Acute Coronary Syndrome treatment.
• The leading Acute Coronary Syndrome companies include Janssen Research & Development, DalCor Pharmaceuticals, Hyloris Pharmaceuticals, and others are evaluating their lead assets to improve the Acute Coronary Syndrome treatment landscape.
• Key Acute Coronary Syndrome pipeline therapies in various stages of development include Milvexian, Dalcetrapib, HY-074, and others.
• In June 2025, a BMJ investigation uncovered serious concerns over data used in ACS trials for ticagrelor (Brilinta), an FDA-approved antiplatelet since 2011, citing inconsistencies in platelet data from two early trials, raising questions about its approval basis.
• In May 2025, the EuroPCR 4D-ACS trial showed that a one-month dual antiplatelet therapy (aspirin + prasugrel) followed by low-dose prasugrel monotherapy significantly reduced bleeding events without increasing ischemic risk post-PCI in ACS patients
• In February 2025, the ACC/AHA/ACEP/NAEMSP/SCAI released updated guidelines for managing acute coronary syndromes (unstable angina, NSTEMI, STEMI), merging previous STEMI and NSTEMI guidance and emphasizing advanced ECG use, serial troponins, and intracoronary imaging

Request a sample and discover the recent breakthroughs happening in the Acute Coronary Syndrome pipeline landscape at https://www.delveinsight.com/report-store/acute-coronary-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Acute Coronary Syndrome Overview
The treatment landscape for Acute Coronary Syndrome (ACS) is undergoing significant transformation as emerging therapies focus on overcoming limitations of standard antiplatelet and anti-inflammatory drugs. With high unmet clinical needs related to drug resistance, bleeding risk, and long-term cardiovascular event recurrence, pipeline agents are being developed to offer more precise, safer, and faster-acting alternatives. Among the most notable candidates are Vicagrel by Jiangsu Vcare Pharmaceutical Technology and Orticumab by Abcentra, both of which represent innovative approaches to ACS management.

Find out more about Acute Coronary Syndrome medication at https://www.delveinsight.com/report-store/acute-coronary-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Acute Coronary Syndrome Treatment Analysis: Drug Profile
Vicagrel - Jiangsu Vcare Pharmaceutical Technology Co., Ltd.
Vicagrel is an innovative antiplatelet agent developed through a collaboration between Jiangsu Vcare and China Pharmaceutical University. Holding complete intellectual property rights, Jiangsu Vcare designed Vicagrel to generate the same active metabolite as clopidogrel but through a novel metabolic pathway. This design aims to bypass clopidogrel resistance and reduce adverse drug interactions commonly observed during co-administration. Vicagrel boasts a faster onset of action and requires a lower dose, making it particularly suitable for emergency use while potentially minimizing dose-related side effects. The company has submitted a New Drug Application (NDA) to the U.S. FDA for Vicagrel capsules, targeting thrombotic cardiovascular and cerebrovascular conditions such as ACS, ischemic stroke, and peripheral arterial disease. The drug is currently in the preregistration stage for Acute Coronary Syndrome.

Orticumab - Abcentra
Orticumab is a first-in-class, fully human IgG1 monoclonal antibody being developed by Abcentra to treat inflammation-driven atherosclerotic events in ACS. Unlike systemic anti-inflammatory treatments, Orticumab adopts a highly targeted mechanism by binding to oxidized LDL (oxLDL), specifically the malondialdehyde-modified apolipoprotein B-100 epitope. This localized action is designed to reduce macrophage activation within unstable plaques, thereby lowering the risk of rupture and subsequent acute coronary events. As an inflammation-modulating biologic, Orticumab presents a promising new approach to long-term cardiovascular protection in ACS and is currently in Phase II clinical development.

Learn more about the novel and emerging Acute Coronary Syndrome pipeline therapies at https://www.delveinsight.com/report-store/acute-coronary-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Acute Coronary Syndrome Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Acute Coronary Syndrome Pipeline Report
• Coverage: Global
• Key Acute Coronary Syndrome Companies: Janssen Research & Development, DalCor Pharmaceuticals, Hyloris Pharmaceuticals, and others.
• Key Acute Coronary Syndrome Pipeline Therapies: Milvexian, Dalcetrapib, HY-074, and others.

Dive deep into rich insights for drugs used for Acute Coronary Syndrome treatment, visit: https://www.delveinsight.com/report-store/acute-coronary-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Acute Coronary Syndrome Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Acute Coronary Syndrome Pipeline Therapeutics
6. Acute Coronary Syndrome Pipeline: Late-Stage Products (Phase III)
7. Acute Coronary Syndrome Pipeline: Mid-Stage Products (Phase II)
8. Acute Coronary Syndrome Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.